A policy for leishmaniasis with respect to the prevention and control of drug resistance

Tropical Medicine and International Health

Volumn 6, Issue 11, 2001, Pages 928-934

  Bryceson, Anthony ^a,b  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b Bull's House   (United Kingdom)

Author keywords

Drug resistance; Leishmaniasis; Treatment

Indexed keywords

ALLOPURINOL; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTILEISHMANIAL AGENT; ANTIMONY; ANTIRETROVIRUS AGENT; ATOVAQUONE; DAPSONE; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; MILTEFOSINE; PAROMOMYCIN; PYRROLE; ROXYTHROMYCIN; SITAMAQUINE; UNCLASSIFIED DRUG;

DISEASE TREATMENT; DRUG PRESCRIBING; DRUG RESISTANCE; LEISHMANIASIS;

ANTIBIOTIC RESISTANCE; DRUG CHOICE; DRUG COST; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG TOLERABILITY; HEALTH CARE POLICY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDIA; LEPROSY; MALARIA; NONHUMAN; PARASITE TRANSMISSION; RELAPSE; REVIEW; RISK; SUDAN; TUBERCULOSIS; VISCERAL LEISHMANIASIS;

ANTIPROTOZOAL AGENTS; DISEASE MANAGEMENT; DISEASE OUTBREAKS; DRUG RESISTANCE; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HEALTH POLICY; HUMANS; LEISHMANIASIS; WORLD HEALTH;

HUMAN IMMUNODEFICIENCY VIRUS; PHLEBOTOMINAE; PROTOZOA;

EID: 0034772197     PISSN: 13602276     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3156.2001.00795.x     Document Type: Review

References (40)

1. Leishmania and human immunodeficiency virus coinfection: The first 10 years
2. Investigation of the spread of human visceral leishmaniasis in central Tunisia
3. Chemotherapy for leishmaniasis: Biochemical mechanisms, clinical efficacy, and future strategies
4. Susceptibility of clinically sensitive and resistant Leishmania to pentavalent antimony in vitro
5. Therapy in man
6. Visceral leishmaniasis unresponsive to antimonial drugs. I. Clinical and immunological studies
7. Visceral leishmaniasis unresponsive to antimonial drugs. II. Response to high dosage sodium stibogluconate or prolonged treatment with pentamidine
8. A comparison of three dosage regimens of sodium stibogluconate in the treatment of visceral leishmaniasis in Kenya
9. Pharmacokinetics of antimony during treatment of visceral leishmaniasis with sodium stibogluconate or meglumine antimoniate
10. Visceral leishmaniasis unresponsive to antimonial drugs. III. Successful treatment using a combination of sodium stibogluconate plus allopurinol
11. Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate
12. Epidemia de leishmaniose visceral no estado do Piaui, Brasil, 1980-1986
13. Relapse of visceral leishmaniasis in patients who were co-infected with human immunodeficiency virus and who received treatment with liposomal amphotericin B
14. Flow cytometric assessment of amphotericin B susceptibility in Leishmania infantum isolates from patients with visceral leishmaniasis
15. A double-blind study on the efficacy of oral dapsone in cutaneous leishmaniasis
16. Rationale of the multi drug regimens recommended by a WHO study group on chemotherapy of leprosy for control programmes
17. Decreased sensitivity to meglumine antimoniate (Glucantime) of Leishmania infantum isolated from dogs after several courses of drug treatment
18. Successful treatment of visceral leishmaniasis with allopurinol plus ketoconazole in a renal transplant recipient after the occurrence of pancreatitis due to stibogluconate
19. Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India
20. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis
21. Experience with roxithromycin in visceral leishmaniasis in north Bihar
22. Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani
23. Clinicoepidemiologic characteristics, prognostic factors, and survival analysis of patients co-infected with human immunodeficiency virus and Leishmania in an area of Madrid, Spain
24. Amphotericin versus sodium stibogluconate in first-line treatment of Indian kala-azar
25. Activity of oral atovaquone alone and in combination with antimony in experimental visceral leishmaniasis
26. Use of an itraconazole/allopurinol combination for the treatment of visceral leishmaniasis in a patient with AIDS
27. Visceral leishmaniasis and HIV-1 co-infection in southern France
28. Visceral leishmaniasis control in India through primary health care system - A successful experiment of district level planning
29. Epidemic visceral leishmaniasis in Sudan: A randomized trial of aminosidine plus sodium stibogluconate versus sodium stibogluconate alone
30. The epidemic of visceral leishmaniasis in western upper Nile, southern Sudan: Course and impact from 1984 to 1994
31. Mefloquine pharmacokinetic-pharmacodynamic models: Implications for dosing and resistance
32. Treatment of kala-azar with oral fluconazole
33. Short-course of oral miltefosine for treatment of visceral leishmaniasis
34. Failure of pentavalent antimony in visceral leishmaniasis in India: Report from the center of the Indian epidemic
35. Aminosidine plus sodium stibogluconate for the treatment of Indian kala-azar: A randomized dose-finding clinical trial
36. Comparison of regimens of amphotericin B deoxycholate in kala-azar
37. Fluconazole plus allopurinol in treatment of visceral leishmaniasis
38. Ketoconazole in the treatment of antimony- and pentamidine-resistant kala-azar
39. Delaying antimalarial drug resistance with combination chemotherapy
40. Clinical pharmacokinetics and pharmacodynamics of artemether-lumefantrine